03 Apr 2020 administrator COVID19, Hočkinov limfom, Hronična limfocitna leukemija, Leukemije, Multipli mijelom, Nehočkinski limfom FINDINGS FROM A RETROSPECTIVE CASE STUDY OF COVID-19 INFECTION IN CANCER PATIENTS IN WUHAN: AN EMPHASIS ON SEVERE EVENTS Analysis of risk factors associated with admission to an intensive care unit, the use of mechanical ventilation or deathDate:30 Mar
02 Apr 2020 administrator Hronična limfocitna leukemija, Nehočkinski limfom Implementation of CAR T-cell therapy in the real world – A round table discussion The Lymphoma Hub is pleased to report a summary of real-world experiences of chimeric antigen receptor (CAR) T-cell implementation as discussed
06 Aug 2019 administrator Hočkinov limfom, Hronična limfocitna leukemija, Nehočkinski limfom Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies Overweight and obesity are a global health problem. During the last 40 years, the number of obese adults increased from 100 million in 1975 (69
02 May 2019 administrator Hočkinov limfom, Hronična limfocitna leukemija, Nehočkinski limfom BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL The American Society for Blood and Marrow Transplantation (ASBMT), Center for International Blood and Marrow Transplant Research (CIBMTR), and
15 Mar 2019 administrator Hronična limfocitna leukemija Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study PURPOSE The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixedduration venetoclax-rituximab compared with